WO2016055681A1 - Procesado y uso de fluidos del tracto reproductivo para mejorar la producción in vitro de embriones de mamífero - Google Patents
Procesado y uso de fluidos del tracto reproductivo para mejorar la producción in vitro de embriones de mamífero Download PDFInfo
- Publication number
- WO2016055681A1 WO2016055681A1 PCT/ES2015/070727 ES2015070727W WO2016055681A1 WO 2016055681 A1 WO2016055681 A1 WO 2016055681A1 ES 2015070727 W ES2015070727 W ES 2015070727W WO 2016055681 A1 WO2016055681 A1 WO 2016055681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biofluids
- embryos
- sperm
- phase
- vitro
- Prior art date
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 37
- 238000000338 in vitro Methods 0.000 title claims abstract description 33
- 210000002257 embryonic structure Anatomy 0.000 title claims abstract description 29
- 238000012545 processing Methods 0.000 title claims abstract description 9
- 241000124008 Mammalia Species 0.000 title claims abstract description 8
- 210000005000 reproductive tract Anatomy 0.000 title abstract description 6
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 72
- 239000001963 growth medium Substances 0.000 claims abstract description 26
- 239000002609 medium Substances 0.000 claims abstract description 24
- 238000011161 development Methods 0.000 claims abstract description 13
- 238000004108 freeze drying Methods 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 230000004720 fertilization Effects 0.000 claims description 24
- 210000002459 blastocyst Anatomy 0.000 claims description 18
- 238000005119 centrifugation Methods 0.000 claims description 15
- 210000001161 mammalian embryo Anatomy 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 9
- 230000001850 reproductive effect Effects 0.000 claims description 8
- 238000005194 fractionation Methods 0.000 claims description 7
- 230000029849 luteinization Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000009928 pasteurization Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000000472 morula Anatomy 0.000 claims 2
- 230000011599 ovarian follicle development Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000005138 cryopreservation Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 3
- 239000007943 implant Substances 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 238000003744 In vitro fertilisation Methods 0.000 abstract 1
- 210000000287 oocyte Anatomy 0.000 description 31
- 239000012071 phase Substances 0.000 description 17
- 238000012549 training Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 210000004340 zona pellucida Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 230000000938 luteal effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000009810 tubal ligation Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000928179 Homo sapiens Agouti-related protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000002282 effect on embryo Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 102000055839 human AGRP Human genes 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/06—Bioreactors or fermenters specially adapted for specific uses for in vitro fertilization
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/43—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Definitions
- the present invention contemplates a method for increasing embryonic quality through the use of in vitro fertilization (IVF) techniques, optionally with pre-incubation of the oocytes in natural biological fluids of specific phases of the reproductive cycle, combined with a method of sperm separation in the middle. of culture supplemented with said fluids and the subsequent fertilization and embryonic culture (EC) in media supplemented with fluids.
- IVF in vitro fertilization
- EC fertilization and embryonic culture
- This invention belongs in general to the field of Assisted Reproduction in mammals, in particular the techniques of sperm training, in vitro fertilization and embryo culture.
- the currently known procedure for obtaining an embryo in vitro involves the performance of different assisted reproduction techniques (ARTs) that differ between laboratories and species, and includes the following steps: 1) obtaining and in vitro maturation (IVM) of the female gametes (oocytes); 2) the preparation and training of male gametes (sperm); 3) the process of in vitro fertilization itself either by co-cultivating the gametes or assisted microinjection of a sperm inside the oocyte, and 4) the CE so that the zygotes reach the desired stage of development, usually the of blastocyst.
- IVM in vitro maturation
- sperm preparation and training of male gametes
- CE the process of in vitro fertilization itself either by co-cultivating the gametes or assisted microinjection of a sperm inside the oocyte
- CE so that the zygotes reach the desired stage of development, usually the of blastocyst.
- FO and / or FU are obtained by different techniques and are generally processed with a single centrifugation and subsequent freezing of the liquid fraction (Carrasco et al. 2008a, Fertile Reprod Dev 20: 808-817; Carrasco et al. 2008b, Reproduction 136: 833-842; Faulkner et al. 2012, Proteomics 12: 2014-223; Lippes and Wagh 1993, Fertile Steril 59: 157-162; Velazquez et al. 2010, Theriogenology 73: 758- 767).
- biofluids have not been used as additives in human ARTs, which opens a new field of research, especially if we consider that, in most cases, the beneficial effect on gametes and embryos is interspecific, that is, that biofluids of one mammal species can be used for ARTs of another different species (Mondisputed et al. 2013, HumReprod 28: 718-728; Rondeau et al.
- Patent-1 (ES 2 323 993 A1, Pilar Coy Fuster and Manuel Avilés Sánchez), which describes a method to increase monospermia in IVF.
- Patent-2 (ES 2 439424 A1, Ignacio Santiago ⁇ lvarez Miguel and Mario Javier Perianes Carrasco) which describes a method to increase the implant potential of mammalian embryos obtained by IVF.
- Patent-3 (WO2006 / 012177, Randall Prather) "Method to decrease the rate of polyspermy in IVF".
- Patent-4 (US 2013/0344595 A1, David K. Gardner, Mark G. Larman and Donald Linck) "Culture media for developmental cells containing elevated concentrations of lipoic acid”.
- Patent-5 (CN 103333855 (A), ZouXiangang and Zhao Yalin) "Sheep embryonic cell culture fluid”.
- the present invention contemplates a method for increasing the quality of mammalian embryos obtained in vitro by means of a system that includes the addition of natural biological fluids (FO and / or FU) of specific phases of the reproductive cycle in the sperm training, IVF and EC.
- natural biological fluids FO and / or FU
- the authors of the present invention have developed, on the one hand, a sperm training system that does not require centrifugations, using the FO and / or FU as a protein additive, which implies great advantages in reducing stress by that the male gametes are subjected during the seminal plasma separation procedure, and thus helps to select those sperm with better DNA quality and integrity. It has been possible to combine both strategies by formulating a new culture medium to select sperm using the Swim-up technique that offers better results than conventional media.
- this invention proposes the introduction of these natural fluids from the reproductive tract, such as FO and FU, into ARTs to improve the quality of embryos obtained in vitro.
- the invention describes a method of obtaining embryos in vitro by adding biofluids to the culture media in each of the process phases.
- Biofluids are obtained from genital devices of mammalian females in specific phases of the reproductive cycle and are previously subjected to a purification and treatment process for their conservation and transport.
- the invention comprises the following steps: a) a method of classification of FO and FU according to the stage of the reproductive cycle in which they are obtained, followed by their fractionation by double centrifugation and subsequent processing by lyophilization and pasteurization.
- IVF in a medium enriched with FO and / or FU.
- the FO is obtained by aspiration by introducing the tip of an automatic pipette through the oviductal ampoule and exerting a manual pressure thus aspirating all the oviductal content.
- said content is centrifuged (between 4000-1 OOOOg for 1-10 minutes at 4 ° C) and the cell pellet and the mucous phase are discarded.
- the FO supernatant is recentrifuged under the same conditions, the aqueous phase being in the upper part and the mucous phase (bottom of the tube) in the lower part. Only the aqueous phase of the FO is aspirated.
- the FU is obtained by aspiration by introducing the tip of an automatic pipette into the uterine horn, exerting an upward manual pressure. Said content is fractionated by double centrifugation under the same conditions as the FO.
- the biofluids are lyophilized between -50 ° C and -60 ° C, for 20-24h with a pressure of 0.040-0.010 millibars. Once the process is finished, they are kept refrigerated until they are used.
- the biofluids obtained from the different species and phases of the cycle are stored in a biobank and can be used both inter-or intraspecific as well as autologous or heterologous. Before using them as additives in a culture medium, the biofluids are redissolved with purified water to their original volume.
- biofluids can be transported at room temperature, maintain their biological properties when rehydrated and can be pasteurized at 72-80 ° C for 10-20 seconds before use, which results necessary for the sanitary guarantees of the product.
- Product activity tests have been performed evaluating the ability of biofluids to harden the pellucid zone (ZP) of the oocyte (Coy et al. 2008b, Reproduction 135: 19-27).
- ZP pellucid zone
- mature oocytes underwent digestion with protease. The results show that the biofluids subjected to the fractionation and conservation process described in this patent maintain their biological activity once they are resuspended and pasteurized.
- the present invention includes the formulation of a new culture medium for sperm selection that we call Swim-up-biofluids.
- a new culture medium for sperm selection that we call Swim-up-biofluids.
- NaHCOs NaCI, KCI, MgS0 4 , K 2 HP0, and CaCI 2 . They are responsible for maintaining the osmolarity and pH of the medium, so their concentration was adjusted to levels similar to those described in the FO. The final osmolarity of the medium remained in the range physiological 280-320mOsm. The concentration of inorganic salts was between 90 and 130 mM.
- concentration of energy substrates within this group are glucose, sodium pyruvate, sodium lactate and sucrose. Concentrations were adjusted to achieve optimum density and viscosity that allowed sperm motility through the medium. The concentration of energy substrates was between 120 and 160 mM.
- the protein source in the new medium we designed, Swim-up-biofluids, the protein source consisted of the addition of 0.1-5% of FO preferably from fractional and treated phase F2 as described in step a). This treatment was compared with BSA, a protein source usually used in training media.
- the Swim-up-biofluids training method was performed by mixing 0.5-1.5ml of semen with 0.5-1.5ml of Swim-up-biofluids medium and allowing the sperm to swim towards the top of the tube for a time of 10-50 min at a temperature of 37-38 ° C. After this time 0.5-1 ml of the middle of the upper part was collected containing the sperm that were used to
- the porcine oocytes are matured in vitro for 42-44h according to the protocols described (Coyetal. 2008b, Reproduction 135: 19-27). After this time, they are mechanically decumulated and 50-55 oocytes are transferred per fertilization well containing only 500 ul of TALP medium (control group) (Matas et al. 2003, Reproduction 125: 133-1141) or TALP supplemented with 0.1 to 5 % of FO, preferably of phase F2 or L1, fractionated and treated as described in step a) (biofluid group).
- the sperm used for IVF were obtained and processed using the Swim-up-biofluid system described in step b).
- the decumulated oocytes can be incubated 30-60 minutes with FO preferably of phase F2 or L1.
- FO preferably of phase F2 or L1.
- the gametes were cocultivated for 18 hours after which the alleged zygotes were fixed and stained to evaluate the results of fertilization. With this method, the rates of monospermia are improved after fertilization.
- the embryonic division was evaluated and subsequently the embryos were transferred to NCSU-23 medium supplemented with 0.1-5% FU preferably from phase L1 or L2 to the blastocyst stage.
- the biofluids were not used in any of the phases of the method, the sperm were trained with the Swim-up-BSA method, the oocytes were fertilized in TALP medium and the zygotes were transferred to NCSU-23 medium for culture. embryonic.
- the quality of the embryos obtained in both groups was evaluated according to morphology (Bó and Mapletoft 2013, Anim Reprod 10: 344-348) and number of cells per blastocyst.
- Experimental work has shown that embryos produced in vitro with the biofluid method divide faster than the control and are of better quality (evaluated as number of cells per blastocyst and ability to hatch).
- Example of embodiment of the invention Method used to obtain embryos by fertilization and in vitro culture using biofluids from different stages of the cycle, checking the improvement in embryonic quality a.- Obtaining, fractioning and controlling the activity of biofluids
- FO and FU are obtained from genitals from animals slaughtered in slaughterhouse for meat consumption.
- human species they can be obtained from donors, from patients undergoing tubal ligation or from women undergoing salpingectomies or hysterectomies for health reasons.
- the biofluids are centrifuged (4000-1 OOOOg for 1-10 minutes at 4 ° C) and the aqueous phase is recentrifuged under the same conditions. This liquid is lyophilized and pasteurized, being ready for use as an additive for culture media after resuspension with purified water.
- the effectiveness of the treatment was estimated by the ability of the FO to cause hardening of the zona pellucida.
- the oocytes matured in vitro are mechanically denied and incubated in FO for 30-60 minutes at 38.5 ° C. After this time the oocytes are incubated with a 0.5% protease solution and the time it takes to digest the ZP is counted.
- Table 1 shows, the treated biofluids maintained their biological activity with respect to untreated biofluids (control):
- N is the number of oocytes used b.- Sperm training without centrifugation in a new medium enriched with biofluids.
- the new culture medium was formulated by adjusting osmolarity, pH and energy substrates and replacing bovine serum albumin (BSA) with biofluids.
- BSA bovine serum albumin
- the training was carried out with ejaculated sperm from males of proven fertilization (12-24 months of age).
- semen was deposited on the Swim-up-biofluid medium for 15-30 minutes at 37-38 ° C. After this time the cells were collected from the top and the sperm concentration was adjusted to 25,000 sperm / ml using TALP culture medium (Matas et al. 2003, Reproduction 125: 133-1141).
- This new method of sperm training was compared with the traditional centrifugation method (Percoll) (Matas et al. 2003, Reproduction 125: 133-1141).
- the quality of the sperm obtained was assessed by its ability to fertilize porcine oocytes previously matured in vitro for 42-44 hours with conventional protocols (Coy et al. 2008b, Reproduction 135: 19-27).
- the oocytes were cocultured with the sperm trained in the different methods for 18 hours. After this time the alleged zygotes were fixed and stained to evaluate the fertilization results (Coy et al. 2008b, Reproduction 135: 19-27).
- PEN percentage of oocytes penetrated
- MONO percentage of monospermia
- SPZ / OO average number of sperm per penetrated oocyte
- SPZ / ZP average number of sperm attached to the zona pellucida
- REN yield, percentage of viable zygotes over the total of the oocytes. Data are expressed as mean ⁇ SEM. Different letters indicate significant differences with P ⁇ 0.05.
- N is the number of oocytes inseminated c- Obtaining embryos by IVF in biofluid supplemented media.
- IVF is performed in a culture medium (TALP) with or without biofluids.
- the oocytes mature under the usual protocols described above and are transferred to the fertilization medium.
- the results of this invention have shown that when the oocytes are inseminated in a culture medium supplemented with FO, the penetration rates are increased while maintaining high levels of monospermia (Table 3). This makes the yield (REN) of the IVF method with biofluids significantly greater, obtaining a greater number of possible embryos.
- N is the number of oocytes inseminated d.- Embryonic culture with biofluids and assessment of the quality of the embryos obtained.
- the zygotes were transferred to culture medium (NCSU-23) supplemented or not with early luteal phase FO for 48 hours where they were grown to 2-4 cell stage. After this time the embryos were transferred to NCSU-23 medium supplemented or not with early luteal phase FU where they were cultured to the blastocyst stage.
- NCSU-23 medium supplemented or not with early luteal phase FU where they were cultured to the blastocyst stage.
- the parameters of division, number of blastocysts in each of the stages of development from early blastocyst to hatched blastocyst
- average number of cells per blastocyst and their functionality were assessed. , evaluated as their ability to hatch (contract and expand rhythmically until they get out of the zona pellucida).
- N is the number of zygotes used
- Control 903 31.7 ⁇ 6.1 to 28.3 ⁇ 5.9 40.0 ⁇ 6.4 0a 0a
- N is the number of zygotes used
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Physics & Mathematics (AREA)
- Clinical Laboratory Science (AREA)
- Hematology (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/517,878 US11208622B2 (en) | 2014-10-08 | 2015-10-07 | Processing and use of reproductive tract fluids to improve the in vitro production of mammalian embryos |
BR112017007213-0A BR112017007213A2 (pt) | 2014-10-08 | 2015-10-07 | "processamento e utilização de fluidos do trato reprodutivo para melhorar a produção in vitro de embriões de mamífero" |
EP15848765.2A EP3205716A4 (en) | 2014-10-08 | 2015-10-07 | Processing and use of fluids of the reproductive tract for improving the in vitro production of embryos of mammals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201400811 | 2014-10-08 | ||
ES201400811A ES2532659B2 (es) | 2014-10-08 | 2014-10-08 | Procesado y uso de fluidos del tracto reproductivo para mejorar la producción in vitro de embriones de mamífero |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016055681A1 true WO2016055681A1 (es) | 2016-04-14 |
Family
ID=52706431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2015/070727 WO2016055681A1 (es) | 2014-10-08 | 2015-10-07 | Procesado y uso de fluidos del tracto reproductivo para mejorar la producción in vitro de embriones de mamífero |
Country Status (5)
Country | Link |
---|---|
US (1) | US11208622B2 (es) |
EP (1) | EP3205716A4 (es) |
BR (1) | BR112017007213A2 (es) |
ES (1) | ES2532659B2 (es) |
WO (1) | WO2016055681A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108060117B (zh) * | 2017-12-01 | 2021-08-20 | 温氏食品集团股份有限公司 | 一种提高猪克隆胚胎发育效率的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2570491A1 (en) | 2004-06-25 | 2006-02-02 | The Curators Of The University Of Missouri | Method to decrease the rate of polyspermy in ivf |
ES2323993B1 (es) | 2006-09-14 | 2010-05-31 | Universidad De Murcia | Metodo para aumentar la monospermia en la fecundacion in vitro. |
JP2010525818A (ja) | 2007-05-01 | 2010-07-29 | ヴィトロライフ スウェーデン アクチボラゲット | リポ酸濃度を高めた発生細胞用培養培地 |
ES2439424B1 (es) | 2012-07-20 | 2014-11-11 | Universidad De Extremadura | Método para aumentar el potencial implantatorio de embriones de mamíferos obtenidos por fecundación in vitro |
CN103333855B (zh) | 2013-06-17 | 2015-03-25 | 青岛森淼实业有限公司 | 一种羊胚胎细胞培养液 |
-
2014
- 2014-10-08 ES ES201400811A patent/ES2532659B2/es active Active
-
2015
- 2015-10-07 BR BR112017007213-0A patent/BR112017007213A2/pt not_active Application Discontinuation
- 2015-10-07 US US15/517,878 patent/US11208622B2/en active Active
- 2015-10-07 EP EP15848765.2A patent/EP3205716A4/en active Pending
- 2015-10-07 WO PCT/ES2015/070727 patent/WO2016055681A1/es active Application Filing
Non-Patent Citations (5)
Title |
---|
ELHASSAN Y. M. ET AL.: "Amino acid Concentrations in fluids from the bovine oviduct and uterus and in KSOM-based culture media.", THERIOGENOLOGY UNITED STATES, vol. 55, no. 9, 1 June 2001 (2001-06-01), pages 1907 - 1918, XP055401714, ISSN: 0093-691X * |
KIM N. H. ET AL.: "Effects of oviductal fluid on sperm penetration and cortical granule exocytosis during fertilization of pig oocytes in vitro.", JOURNAL OF REPRODUCTION AND FERTILITY ENGLAND MAYO, vol. 107, no. 1, 1996, pages 79 - 86, XP055426726 * |
LLOYD R. E. ET AL.: "Effects of oviductal fluid on the development, quality, and gene expression of porcine blastocysts produced in vitro.", vol. 137, no. 4, April 2009 (2009-04-01), Cambridge , England, pages 679 - 687, XP055426731, ISSN: 1741-7899 * |
RONGFENG, L. ET AL.: "Development, freezability and amino acid consumption of bovine embryos cultured in synthetic oviductal fluid (SOF)medium containing amino acids at oviductal or uterine-fluid concentrations.", THERIOGENOLOGY UNITED STATES, vol. 66, no. 2, 15 July 2006 (2006-07-15), pages 404 - 414, XP027930161, ISSN: 0093-691X * |
See also references of EP3205716A4 * |
Also Published As
Publication number | Publication date |
---|---|
ES2532659A1 (es) | 2015-03-30 |
US20170313966A1 (en) | 2017-11-02 |
US11208622B2 (en) | 2021-12-28 |
EP3205716A1 (en) | 2017-08-16 |
EP3205716A4 (en) | 2018-04-04 |
ES2532659B2 (es) | 2015-09-08 |
BR112017007213A2 (pt) | 2018-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Skidmore | Reproduction in dromedary camels: an update | |
Enright et al. | Culture of in vitro produced bovine zygotes in vitro vs in vivo: implications for early embryo development and quality | |
Baldassarre et al. | Advanced assisted reproduction technologies (ART) in goats | |
Lazzari et al. | Short-term and long-term effects of embryo culture in the surrogate sheep oviduct versus in vitro culture for different domestic species | |
Stout | Equine embryo transfer: review of developing potential | |
Pope | Aspects of in vivo oocyte production, blastocyst development, and embryo transfer in the cat | |
Paramio et al. | Assisted reproduction technologies in goats | |
US20040121303A1 (en) | Cryopreservation of sperm | |
Tibary et al. | Update on reproductive biotechnologies in small ruminants and camelids | |
JP2008536524A (ja) | 不妊に関連する酸化ストレス治療のためのn−アセチルシステインアミド(nacアミド) | |
Presicce | Reproduction in the water buffalo | |
Davachi et al. | The effect of conspecific ampulla oviductal epithelial cells during in vitro maturation on oocyte developmental competence and maturation-promoting factor (MPF) activity in sheep | |
Rath et al. | In vitro development to blastocysts of early porcine embryos produced in vivo or in vitro | |
Srirattana et al. | Current status of assisted reproductive technologies in buffaloes | |
Hasler et al. | In vitro fertilization | |
Locatelli et al. | Successful use of oviduct epithelial cell coculture for in vitro production of viable red deer (Cervus elaphus) embryos | |
US20090055945A1 (en) | Method for Producing Nuclear-Transplanted Egg | |
Rath et al. | Successful gamete intrafallopian transfer (GIFT) in the porcine | |
ES2756773T3 (es) | Método para aumentar el índice de implantación del embrión en el útero de la madre en mamíferos, uso de una cantidad eficaz de lectina de unión al beta-galactósido o de derivados de la misma, de lectina de unión al beta-galactósido o de derivados y producto | |
ES2532659B2 (es) | Procesado y uso de fluidos del tracto reproductivo para mejorar la producción in vitro de embriones de mamífero | |
Douet et al. | Exposure to follicular fluid during oocyte maturation and oviductal fluid during post-maturation does not improve in vitro embryo production in the horse | |
Pope | Thirty years of assisted reproductive technology in the domestic cat: A selected summary | |
Abeydeera et al. | Effect of incubation temperature on in vitro maturation of porcine oocytes: nuclear maturation, fertilisation and developmental competence | |
Mermillod | In vitro production of ruminant embryos: results, limits and perspectives | |
El-Sayed et al. | Assessment of embryo production of Dromedary (Camelus dromedarius) using two semen sources and two in vitro fertilization techniques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15848765 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015848765 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015848765 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15517878 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017007213 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112017007213 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170407 |